Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**[18F]fluoro-PEG-folate** is a radiopharmaceutical PET tracer designed for **targeted imaging of folate receptor (FR)-expressing cells**, primarily for the detection of inflammation and cancer. It binds both FR-α (commonly overexpressed in certain cancers) and FR-β (on activated macrophages in inflamed tissues). The radiotracer is synthesized by conjugating a fluorine-18 label (via a polyethylene glycol [PEG] linker) to folic acid, enhancing its pharmacokinetics and specificity. In clinical studies, [18F]fluoro-PEG-folate demonstrated rapid blood clearance, low background uptake, and high target-to-background ratios, making it particularly effective for imaging inflamed joints in rheumatoid arthritis and potentially other inflammatory and oncologic conditions. Its mechanism of action is **receptor-mediated targeting** of FR-expressing cells, facilitating sensitive whole-body PET imaging for diagnostic and monitoring purposes[2][1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]fluoro-PEG-folate.